SCHEMBL29561775

SCHEMBL29561775

COc1cccc(-c2nc(Nc3cccc(S(C)(=O)=O)c3)nc(NC(C)C)n2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNH3 Q9ULD8 5/20 0.51
▸ IDH1 O75874 6/20 0.51
▸ IDH2 P48735 1/20 0.51
▸ CDK9 P50750 2/20 0.48
▸ CCNT1 O60563 1/20 0.48
▸ CCNE1 P24864 1/20 0.48
▸ CDK2 P24941 1/20 0.48
▸ AURKA O14965 1/20 0.46
▸ MAP4K4 O95819 1/20 0.46
▸ ABL1 P00519 1/20 0.46
▸ LCK P06239 1/20 0.46
▸ MET P08581 1/20 0.46
▸ PDGFRB P09619 1/20 0.46
▸ FGFR1 P11362 1/20 0.46
▸ FLT1 P17948 1/20 0.46
▸ KDR P35968 1/20 0.46
▸ FLT3 P36888 1/20 0.46
▸ MAPK8 P45983 1/20 0.46
▸ MAPK9 P45984 1/20 0.46
▸ GSK3A P49840 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15102464 1.00 KCNH3 (0.51) KCNH3IDH1IDH2CDK9CCNT1
SCHEMBL15102435 0.86 IDH1 (0.53) KCNH3IDH1IDH2CDK9CCNT1
SCHEMBL29560403 0.86 IDH1 (0.53) KCNH3IDH1IDH2CDK9CCNT1
SCHEMBL16392202 0.86 TNNI3K (0.46) IDH1CDK9CCNT1CCNE1CDK2
SCHEMBL16388209 0.85 CDK9 (0.50) IDH1CDK9CCNT1CCNE1CDK2
SCHEMBL15102285 0.85 IDH1 (0.53) KCNH3IDH1IDH2POLBCA1
SCHEMBL29561084 0.85 IDH1 (0.53) KCNH3IDH1IDH2POLBCA1
SCHEMBL15102250 0.84 IDH1 (0.52) KCNH3IDH1IDH2CDK9CCNT1
SCHEMBL29560264 0.84 IDH1 (0.71) IDH1IDH2
SCHEMBL29560845 0.84 IDH1 (0.52) KCNH3IDH1IDH2CDK9CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4647076-A2 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE Les Laboratoires Servier (FR) 2025-11-12 — — EP disclosed
EP-3984997-B1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER LAB (FR) 2025-07-30 — — EP disclosed
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2023-08-10 — — US disclosed
US-11505538-B1 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2022-11-22 — — US disclosed
US-20220348554-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2022-11-03 — — US disclosed
CN-108912066-B Therapeutically active compounds and methods of use thereof 安吉奥斯医药品有限公司 2022-06-24 — — CN disclosed
EP-3984997-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE Les Laboratoires Servier SAS (FR) 2022-04-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220348554-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT KCNH3 4722/4885IDH1 172/4885IDH2 110/4885
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE MCL1, TP53, BRDT KCNH3 4722/4885IDH1 172/4885IDH2 110/4885
US-11505538-B1 Therapeutically active compounds and their methods of use MCL1, TP53, BRDT KCNH3 4722/4885IDH1 172/4885IDH2 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback